Selinexor Enhances NK Cell Activation Against Malignant B Cells <i>via</i> Downregulation of HLA-E.

Fisher, Jack G; Walker, Christopher J; Doyle, Amber Dp; Johnson, Peter Wm; Forconi, Francesco; Cragg, Mark S; Landesman, Yosef; Khakoo, Salim I; Blunt, Matthew D

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E.

Fisher, Jack G; Walker, Christopher J; Doyle, Amber Dp; Johnson, Peter Wm; Forconi, Francesco; Cragg, Mark S; Landesman, Yosef; Khakoo, Salim I; Blunt, Matthew D.

Afiliação

Fisher JG; School of Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.
Walker CJ; Research & Translational Development, Karyopharm Therapeutics, Newton, MA, United States.
Doyle AD; School of Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.
Johnson PW; School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
Forconi F; School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
Cragg MS; School of Cancer Sciences, University of Southampton, Southampton, United Kingdom.
Landesman Y; Research & Translational Development, Karyopharm Therapeutics, Newton, MA, United States.
Khakoo SI; School of Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.
Blunt MD; School of Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.

Front Oncol ; 11: 785635, 2021.

Article em En | MEDLINE | ID: mdl-34926302

Palavras-chave

CLL (chronic lymphocytic leukemia); HLA-E; NK cells; NKG2A; XPO1; lymphoma; natural killer cells; selinexor

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido